Bob Cathcart

CEO

AiM Medical Robotics (Worcester, Ma. USA) is developing the world’s first MRI compatible surgical robot. Our surgical robotic platform simultaneously combines surgical planning and procedure, with MR functional robotics that provide precise trajectory guidance for neurosurgical procedures. As a Company, we aim to eliminate existing error and revision rates seen today, while reducing procedure time, to support better patient outcomes. Furthermore, our system is light weight, portable and will work seamlessly in the existing workflow in both the MRI suite and the Operating Room. We have licensed our technology from the Worcester Polytechnic Institute (WPI) outside of Boston. The inventors at WPI have received over $15m of NIH and NCI grants which have been used to develop working prototypes of the robotic system. The technology has been validated in bench top studies, animal studies, and in a 30 patient IRB trial at the Brigham and Women’s Hospital in Boston. The technology is supported by 3 issued patents and 11 pending patents. We have completed a Working Prototype of our commercial robotic system with the support of our engineering partners from Triple Ring Technologies. We have a distinguished Clinical Advisory Board representing surgeons from the Cleveland Clinic, Emory University, Northwestern, and the Albany Medical Center. We have raised a $3.5m Seed round of financing, led by IQ Capital (London) and Surrey Capital Partners (NYC), and are currently seeking to raise a $15m A round.

Therapeutic: Robotics & Neurosurgery

Alio (Broomfield, CO, USA) provides medical-grade, actionable data to dialysis patient’s clinical care team. Our platform monitors serum potassium, hemoglobin, hematocrit, and basic vitals through a single, noninvasive, wearable device (the Alio SmartPatch). The clinical care team receives notifications through a portal if patient metrics are abnormal and require follow-up. For the dialysis patient, the experience is seamless - the system is entirely plug-and-play and works out of the box, with no pairing or WiFi setup required.

Therapeutic: Remote Patient Monitoring & Dialysis Patient Remote Monitoring

Daniel Odermatt

Senior Director

Senhance® Surgical System by Asensus Surgical (Durham, North Carolina, United States) is turbocharging the Digital Laparoscopy landscape, providing surgeons with an unprecedented level of control, integrating innovative technological advances to help surgery become more instinctive, more responsive and more focused. It builds upon laparoscopy by integrating augmented intelligence through the Intelligent Surgical Unit™(ISU™) to increase surgeon control and machine learning to reduce variability. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics.

Therapeutic: Surgery & Laparoscopic

Enrique Vega

CEO

Azalea Vision (Ghent, Belgium) is developing an autonomous Smart Iris (embedded inside a contact lens) with a dynamic aperture optic mimicking a functional iris, for patients suffering from lack of depth of focus, presbyopia, lack of visual acuity, glare, halos, starburst or photophobia. The patients keep the control over the therapy with a smart phone, to accommodate the functioning of the bionic iris to any evolution of their symptoms or needs during their daily life.

Therapeutic: Ophthomology & Smart Contact Lens

Celero Systems (Boston Area, MA, US) has developed and patented a long-acting physiological monitoring and drug delivery capsule. The smart capsule covers a range of enabling technologies including the ability to monitor physiology from inside the GI tract of a patient, and to respond to the detected physiology to treat a range of medical conditions. The capsule resides within the upper GI from 7 to 14 days and is cloud enabled allowing for physiological data to be shared with physicians resulting in improved patient care.

Therapeutic: Precision Drug Delivery with Physiological Monitoring

Evan Luxon

CEO

Centese (Omaha, NE, USA) has developed Thoraguard, an FDA-cleared digital medical device that precisely monitors thoracic surgery patients as they recover post-op so they can return home as soon as possible. Thoraguard reduces the length of stay by a full day, which results in direct financial savings for hospitals. The company has vetted its commercial strategy through proof-of-concept pilots at marquee accounts around the country with minimal effort and is raising an $8M Series B round to fund rapid commercial expansion.

Therapeutic: Surgery

Thomas Looby

CEO

Conavi Medical is a commercial-stage medical device company. Its flagship product is the Novasight Hybrid system, which is the first and only coronary imaging system to combine co-registered ultrasound (IVUS) and optics (OCT). Novasight has 510(k) clearance and has used by a number of luminary academic hospitals and key opinion leaders in the US. The company is seeking investment to further its base of clinical evidence, expand its commercial footprint in the US, and ready the system for broad market adoption.

Therapeutic: Interventional Cardiology (Coronary)

Kate Dilligan

Founder & CEO

Amma by Cooler Heads Care (San Diego, CA, USA) is the first FDA cleared medical device that allows chemotherapy patients to keep their hair while being profitable for infusion centers.

Therapeutic: Oncology

James Hong

CEO

Filtro Medical (San Jose, CA, USA) is aiming to optimize intravenous cancer treatment by reducing systemic toxicity using a novel drug capture catheter based device.

Therapeutic: Oncology

Fluid Biomed (Calgary, Alberta, Canada) is a VC-backed pre-clinical medical device start-up that has developed the world’s first bio-resorbable stent to cure brain aneurysms. Our innovative polymer technology allows physicians the versatility of treating a wider variety of aneurysms more safely and efficiently. Backed by years of laboratory research, a strong IP and tech transfer position, and contract manufacturing partners, the company is opening a $10M Series A round to launch human clinical trials.

Therapeutic: Neurovascular

Harlee Sorkin

CEO

InterShunt (Plymouth, MN) is an early clinical stage medical device company that is developing a catheter for the treatment of heart failure. Our implant-free approach creates a small opening between two chambers of the heart called an interatrial shunt that offloads elevated left atrial pressure. This relieves congestion and allows patients to breathe so that they can maintain an independent lifestyle. Interatrial shunting is one of the most promising emerging therapies for heart failure, our single greatest unmet medical need.

Therapeutic: Cardiovascular & Heart Failure

Invenio Imaging (Santa Clara, CA, USA) is a medical device start-up based in Santa Clara, CA dedicated to advancing the care of cancer patients by combining intraoperative fresh tissue imaging with artificial intelligence. Our technology, the NIO® Laser Imaging System, has been used in over 2500 cancer treatment procedures at major cancer centers both in the US and in Europe. In 2021 Invenio received a Medical Design Excellence Award, was selected to be a Rosenman Innovator, and received CE Mark to commercialize in Europe. The NIO uses Stimulated Raman Histology to provide microscopic images of fresh tissue specimens in minutes. Digital images can be sent for immediate review by pathology allowing for closer collaboration between surgery and pathology. The NIO has now been used in over 2500 cases at sites across the United States and in Europe.

Therapeutic: Imaging

Vance Clement

CEO

Lineus Medical (Fayetteville, AR, United States) is the developer of SafeBreak Vascular, the first FDA cleared break-away device for peripheral IV lines. When a damaging force is placed on an IV line, SafeBreak separates to protect the line. Upon separation, a valve on the patient side of the line closes to prevent blood loss, and a valve on the IV pump side closes to prevent medication loss. In a randomized controlled trial, SafeBreak was shown to reduce IV restarts by 44%

Therapeutic: Vascular Access

Peymon Ghazi

CEO

MALCOVA (Newark, California, USA) is an early-stage med dev start-up focused on improving breast cancer diagnostics for all women, but particularly those with dense breasts, via a safe, fast, comfortable, and patient-specific dedicated breast cancer imaging device.

Therapeutic: Imaging

Reid Rutherford

Co-Founder & CEO

The Melzi Sharps Finder by Melzi Surgical (Los Altos, California, USA) is a U.S. FDA registered device designed to locate instruments, needles, broken pieces and fragments, or sharp objects that have been lost inside a patient during surgery. The Melzi Sharps Finder is an easy-to-use hand tool capable of working in a 5mm trocar for laparoscopic and robotic surgeries and can also be used in open surgery. In a lab study, testing results with the Melzi Sharps Finder show detection of 13mm, 17mm, and 26mm needles with a 95% reliability rate.

Therapeutic: Surgery; Robotic, Laparoscopic and Open Procedures

Nanochon (Washington, DC, USA) is developing a minimally invasive implant for treating cartilage damage and loss in the knee. Targeting surface cartilage, the Chondrograft(TM) device use novel nanomaterial and a 3D printed design to deliver better short term outcomes through mechanical stability, and true longevity by supporting hyaline cartilage growth.

Therapeutic: Orthopedics-Spine, Spine Medicine & Joint Preservation

David Giarracco

CEO

Noninvasix (Galveston, TX, USA) will be the first company to non-invasively monitor the severity of sepsis and septic shock, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real-time. Incorporating Noninvasix into the ICU workflow allows clinicians to more quickly and accurately diagnose their critically ill patients and tailor treatments to improve outcomes. Future developments, enhancements and evidence will expand the use and clinical impact of our technology into other indications and settings.

Therapeutic: ICU-Critical Care & Vital Signs Monitoring

nView medical (Salt Lake City, UT) develops breakthrough image guidance technology for surgery. We use AI image reconstruction to provide 3D images with an order of magnitude less radiation and less time. We provide AI-enabled guidance as well as surgical navigation. The nView s1 system is FDA cleared, clinically proven and in commercial stage.

Therapeutic: Imaging & Surgical Guidance

Ruben de Francisco

CEO

Onera Health (Eindhoven, The Netherlands) is a Onera Health is a leader in transforming diagnostics and monitoring. Their breakthrough technologies are poised to help millions of people struggling with health ailments and chronic conditions in a variety of medical fields, including sleep, neuro, cardiac and respiratory care, ultimately improving the health and quality of life for patients around the world. The innovative solutions provide comprehensive physiological and health-related data to physicians to optimize patient care and reduce healthcare costs. Onera’s first area of focus is Sleep Health.

Therapeutic: Diagnostics, Sleep Diagnostics and Monitoring Solutions

Samuel Owen

Founder & CEO

Otolith Labs (Washington, D.C.) has developed the first symptom management treatment for chronic vertigo, a five million US patient population. The wearable, FDA Breakthrough designated technology has been shown to be more than 3x as effective as a placebo in a recent 100-person trial. Chronic vertigo represents an $8 billion US market which currently has zero symptom management solutions.

Therapeutic: ENT

Dean Hu

CEO

As part of the >65,000 rectosigmoid colon resections in the U.S. annually, surgeons will create a temporary ostomy to protect from anastomosic leaks. But these ostomies themselves are a huge source of morbidity, complications, healthcare costs, hated by patients and they are often not reversed at all. Savage Medical has developed an easy-to-use surgical device that replaces the need for these ostomies, saving over $60,000 per patient while addressing a (conservatively) $4 billion worldwide market.

Therapeutic: Surgery & Oncology

Timothy Still

CEO, President & Board Member

Sense-Biodetection, Inc. (Milford, MA, USA; Oxford and Cambridge, UK) This proprietary nucleic acid amplification technology (NAAT) is optimized to functions that performs a polymerase chain reaction without the prolonged temperature cycling used in traditional RT-PCR. Sense’s Veros™ COVID-19 is a single-use (disposable) automated device that performs a rapid nucleic acid amplification test for the qualitative detection of SARS-CoV-2 viral RNA. Following reverse transcription of the SARS-CoV-2 viral RNA target, a proprietary enzymatic process is used to separate the two strands of the resulting double-stranded DNA resulting in a controlled exponential amplification process.

Therapeutic: Diagnostics

David Narrow

CEO

Sonavex (Baltimore, MD) is a venture-backed clinical stage medtech company spun out from Johns Hopkins with two FDA clearances. The company’s technology uses deep learning and AI to improve arteriovenous fistula (AVF) maturation times for dialysis patients. Sonavex’s technology enables staff at the dialysis clinic to rapidly collect volumetric flow rate, diameter, and depth in just seconds during existing visits via a bioresorbable implant (EchoMark) and an automated 3D ultrasound (EchoSure) to enable early decision-making and reduce catheter time.

Therapeutic: Renal & Dialysis

Jeff Halbrecht

Founder

The Patella LIFT procedure by ZKR Ortho (San Francisco, CA, USA) was developed to treat patients suffering from patellofemoral cartilage degeneration, a painful condition particularly pronounced during running, stair climbing or squatting. Conservative therapy solutions often fail. The only remaining solutions are complex surgeries such as knee replacement or osteotomy. The LIFT procedure is a 30 minute outpatient surgery that offers immediate ambulation with rapid reduction of pain.

Therapeutic: Orthopedics-Spine